Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on the rapid growth of its PFA products and increasing competitiveness in the electrophysiology and vascular intervention sectors [5][9]. Core Insights - The company is expected to achieve total revenues of RMB 25.78 billion, RMB 32.40 billion, and RMB 40.60 billion for the years 2025 to 2027, with growth rates of 24.78%, 25.70%, and 25.31% respectively. The net profit attributable to shareholders is projected to be RMB 8.34 billion, RMB 10.57 billion, and RMB 13.40 billion for the same years, with growth rates of 23.95%, 26.73%, and 26.70% respectively [6][9]. - The company has a strong position in the cardiovascular intervention field, with a comprehensive product layout that includes electrophysiology and vascular intervention devices. The introduction of new PFA products is expected to drive significant revenue growth [11][15]. Summary by Sections Market Performance - The closing price of the company's stock is RMB 229.38, with a market capitalization of RMB 32,349.47 million. The stock has seen a yearly high of RMB 466.07 and a low of RMB 223.48 [3]. Financial Forecasts - The company anticipates revenue growth from RMB 1,650 million in 2023 to RMB 4,060 million in 2027, with a compound annual growth rate (CAGR) of 35.71% from 2023 to 2024 and 25.31% from 2025 to 2027. Net profit is expected to grow from RMB 534 million in 2023 to RMB 1,340 million in 2027, with a CAGR of 49.13% from 2023 to 2024 and 26.70% from 2025 to 2027 [7][9]. Business Overview - The company has established itself as a leading manufacturer in the domestic electrophysiology and vascular intervention market, focusing on coronary access and cardiac electrophysiology. The introduction of PFA products is expected to enhance its competitive edge [8][15]. - The company has successfully participated in domestic alliance procurement, securing a significant market share in coronary access products, which now account for nearly 90% of its offerings [8][11]. Growth Drivers - The increasing prevalence of atrial fibrillation due to an aging population is expected to drive demand for PFA devices, with the market projected to reach RMB 163.15 billion by 2032, growing at a CAGR of 43.73% from 2025 to 2032 [8][59]. - The company has completed over 2,000 PFA procedures by August 2025, indicating strong market acceptance and growth potential for its new products [78]. Competitive Landscape - The domestic electrophysiology market is currently dominated by foreign brands, but the company is positioned to capture market share through competitive pricing and product quality improvements following recent procurement agreements [63][70].

Group 1 - The Ministry of Industry and Information Technology of China announced the construction of national computing power interconnection nodes to enhance the efficiency and service level of public computing resources, promoting high-quality development in the computing power sector [1] - Major US tech stocks, including Amazon, Google, Microsoft, and Meta, reported a significant increase in capital expenditures, projected to reach $660 billion by 2026, representing a 60% year-on-year growth [1] - Domestic internet giants like Tencent, Alibaba, and Baidu are intensifying efforts to attract users to AI applications, which is expected to significantly increase the number of active users in AI apps [1] Group 2 - As of February 10, 2026, the STAR Market 50 Index rose by 0.92%, with notable increases in stocks such as Chipone Technology (up 7.08%) and Shengke Communication (up 5.81%) [2] - The STAR Market 50 Index reflects the performance of the 50 most representative technology companies in the STAR Market, with the top ten weighted stocks accounting for 56.22% of the index [2] - The STAR Market 50 Enhanced ETF closely tracks the STAR Market 50 Index, indicating strong market interest in technology-focused investment vehicles [2]

数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 截至2026年2月10日 10:28，中证医药及医疗器械创新指数(931484)上涨0.50%，成分股海思科上涨 3.59%，药明康德上涨2.11%，康龙化成上涨1.76%，惠泰医疗上涨1.75%，兴齐眼药上涨1.66%。医疗创 新ETF(516820)上涨0.27%，最新价报0.37元。 消息面上，韩国一家数字医疗初创企业9日说，已开发出一款基于人工智能(AI)的数字诊断平台，可以 帮助人们在家尽早发现心脏病发作的先兆。 平安证券指出，2026年设备更新政策持续加码，叠加紧密型县域医共体建设与强基工程推进，基层医疗 设备规模化采购空间打开；国产头部企业如迈瑞医疗、联影医疗、开立医疗招投标金额同比分别增长 36%、34%、77%，行业向上拐点趋势明确。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备 ...

Core Viewpoint - The performance of the Zhuhai-Hong Kong-Macao Greater Bay Area Development Theme Index and its related ETF reflects the overall performance of companies benefiting from the development of the Greater Bay Area, with notable movements in specific constituent stocks [1][2]. Group 1: Index Performance - As of February 10, 2026, the Zhuhai-Hong Kong-Macao Greater Bay Area Development Theme Index (931000) increased by 0.02%, with notable gains from stocks such as Zhaochi Co. (+9.96%) and Mingyang Smart Energy (+1.56%) [1]. - The Greater Bay Area ETF (512970) showed a mixed performance, with a recent price of 1.52 yuan and a cumulative increase of 2.91% over the past week as of February 9, 2026 [1]. Group 2: Liquidity and Trading Data - The trading volume for the Greater Bay Area ETF was reported at 0.00 yuan, with an average daily trading volume of 711,700 yuan over the past month [1]. - The Sharpe ratio for the Greater Bay Area ETF over the past year was 1.41, indicating a favorable risk-adjusted return [1]. Group 3: Drawdown and Fees - The maximum drawdown for the Greater Bay Area ETF year-to-date was 5.52%, with a relative benchmark drawdown of 0.02% [1]. - The management fee for the Greater Bay Area ETF is set at 0.15%, while the custody fee is 0.05% [1]. Group 4: Index Composition - As of January 30, 2026, the top ten weighted stocks in the Zhuhai-Hong Kong-Macao Greater Bay Area Development Theme Index accounted for 44.55% of the index, with China Ping An, Luxshare Precision, and BYD among the leading constituents [2][3]. - The index includes a maximum of 50 Hong Kong market securities, 300 companies from the Shanghai-Hong Kong-Shenzhen market, and 100 mainland market securities, all selected based on their alignment with the Greater Bay Area development theme [2].

中证智能财讯 惠泰医疗（688617）2月10日公告，基于对公司未来发展前景的信心及长期投资价值的认 可，为增强投资者信心并建立健全长效激励机制，公司计划以自有资金通过集中竞价交易方式回购部分 股份，回购资金总额不低于1.5亿元且不超过2亿元，回购价格上限为315元/股，回购期限为董事会审议 通过之日起10个月内。本次回购股份将在未来适宜时机用于员工持股计划或股权激励。公司股票2月9日 收盘价为229.38元/股。 2025年前三季度，公司实现营业总收入18.67亿元，同比增长22.47%；归母净利润6.23亿元，同比增长 18.02%。 核校：孙萍 按回购价格上限测算，预计回购股份数量为47.62万股至63.49万股，占公司总股本的0.34%至0.45%。公 司表示，本次回购不会对公司的日常经营、财务、研发和未来发展产生重大影响，公司有能力支付回购 价款。若回购股份未能在三年内转让完毕，将依法予以注销。 惠泰医疗是一家专注于电生理和介入类医疗器械的研发、生产和销售的高新技术企业，已形成了以完整 冠脉通路和心脏电生理医疗器械为主导，外周血管和非血管介入医疗器械为重点发展方向的业务布局。 ...

Important Matters - Evert plans to acquire 100% of Shengpu shares, with stock resuming trading on February 10 [1] - Hainan Mining intends to acquire 69.9% stake in Fengrui Fluorine Industry, with stock resuming trading on February 10 [1] - Runtou Co., which has seen its core product disperse dye prices rise by approximately 5000 yuan per ton recently, has achieved two consecutive trading limit increases [1] - Zhejiang Longsheng has announced another price adjustment for certain types of disperse dyes on February 8, with price sustainability dependent on supply and demand [1] - Taisheng Wind Power's rocket fuel storage tank production line is designed for an annual capacity of 60 tanks, expected to be operational by mid-2026 [1] - Dingsheng Technology has signed a cooperation framework agreement with Huineng Technology for solid-state batteries and the new energy industry [1] - Microelectrophysiology has received EU MDR certification for its magnetic navigation ablation catheter and star high-density mapping catheter [1] - Yuandong Bio has completed the first dosing of the Phase I clinical trial for the EP-0210 monoclonal antibody injection [1] - Xinyi Sheng has mass-produced and delivered 1.6T optical modules, while advancing the development of 3.2T, 6.4T, and 12.8T products [1] Investments, Contracts, and Collaborations - Mengguli plans to invest 929 million yuan to build a project for an annual production of 30,000 tons of lithium-ion battery cathode materials [1] - Zhiguang Electric's subsidiary has signed a 1.004 billion yuan contract for energy storage systems [1] - Daily Interaction's wholly-owned subsidiary intends to increase capital by 10 million yuan in Yuntong Shuda [1] - Jinhui Co. plans to acquire 100% of Fusheng Mining for 210 million yuan, which holds a gold mining right with an annual production capacity of 50,000 tons [1] - Yuanjie Technology intends to invest 1.251 billion yuan to build a second-phase research and production base for optoelectronic communication semiconductors, focusing on high-speed optical chips [1] - Zhongke Shuguang plans to issue convertible bonds to raise no more than 8 billion yuan for advanced computing cluster systems aimed at artificial intelligence [1] Share Buybacks - Huitai Medical plans to repurchase shares worth 150 million to 200 million yuan for employee stock ownership plans or equity incentives [2] - Kaiying Network intends to repurchase shares worth 100 million to 200 million yuan [2] - Dianzhi Technology plans to repurchase shares worth 100 million to 200 million yuan [2]

近5日资金流向一览见下表： 证券之星消息，截至2026年2月9日收盘，惠泰医疗(688617)报收于229.38元，下跌0.27%，换手率 0.52%，成交量7315.0手，成交额1.67亿元。 2月9日的资金流向数据方面，主力资金净流入1289.18万元，占总成交额7.71%，游资资金净流出 1122.48万元，占总成交额6.71%，散户资金净流出166.7万元，占总成交额1.0%。 惠泰医疗2025年三季报显示，前三季度公司主营收入18.67亿元，同比上升22.47%；归母净利润6.23亿 元，同比上升18.02%；扣非净利润6.02亿元，同比上升18.5%；其中2025年第三季度，公司单季度主营 收入6.54亿元，同比上升24.77%；单季度归母净利润1.98亿元，同比上升6.77%；单季度扣非净利润1.91 亿元，同比上升6.1%；负债率12.24%，投资收益1390.22万元，财务费用-811.65万元，毛利率73.19%。 惠泰医疗（688617）主营业务：公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高 新技术企业,已形成了以完整冠脉通路和电生理医疗器械为主导,外周血管和神经介入医 ...

Industry and Company Overview - The medical consumables sector showed a slight increase, with the sector index closing at 6067.61 points, up by 0.35% [2] - The performance of leading companies in the medical consumables sector included Maipu Medical (+8.5%), Hualan Biological (+7.5%), and Zhend Medical (+6.7%), while underperformers included Microelectrophysiology (-2.9%) and Daobo Medical (-3%) [2] Market Valuation Metrics - As of February 6, the medical consumables sector had a PE ratio of 36.1X, down by 0.23X from the previous week, with a one-year high of 40.1X and a low of 28.88X; the PB ratio was 2.61X, with a one-year high of 2.92X and a low of 2.13X [4] Recent Developments - Microelectrophysiology's product, a disposable intracardiac ultrasound imaging catheter, has been approved for market release, enhancing its core product offerings in cardiac intervention and filling a gap in integrated ultrasound imaging and electrophysiological mapping solutions [5] Investment Recommendations - There is a high certainty of continued performance recovery for some high-value consumable companies, driven by recent approvals of innovative products and overseas business development, which are expected to create new growth points outside of centralized procurement [6] - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the orthopedic implants, cardiovascular intervention devices, and neurosurgical implants sectors, as well as those with advantages in rehabilitation and chronic disease management [6][7]

Market Overview - Technology stocks continue to support the rise of US markets, with the S&P 500 up 0.47%, Dow Jones up 0.04%, and Nasdaq up 0.90% [1] - Major tech companies like Microsoft rose over 3%, Nvidia up 2.5%, while Apple fell over 1% [1] - The chip index increased by over 1%, outperforming the market, with AMD and Broadcom both rising over 3% [1] Chinese Stocks - The Chinese concept stock index saw a slight increase, with Mingda Jiahe rising over 93%, Xuniao Software up over 48%, and Huami Technology up about 27% [2] - New Oriental experienced a decline of over 4% [2] Currency and Commodities - The US dollar index fell for two consecutive days, reaching a one-week low, while the offshore RMB broke the 6.92 mark for the first time in nearly three years [3] - Bitcoin dropped over 6% from its daily high, falling below $69,000, before slightly recovering [3] - Gold prices rose over 2%, surpassing $5,000, with silver prices increasing nearly 9% [3] Technology Developments - Elon Musk announced that SpaceX will shift its focus to building a "self-growing city" on the Moon before advancing its Mars plans [4] - Apple is reportedly planning to launch the iPhone Flip, prompting Samsung Display to consider expanding OLED panel production [5] - Altman stated that ChatGPT's growth has "recovered to over 10%" and plans to launch a new model this week [6] Semiconductor and Storage Market - Counterpoint reported that memory prices surged by 80%-90% quarter-on-quarter in Q1, marking a historic increase [7] - The price of general server DRAM significantly increased, with contract prices for 64GB RDIMM rising from $450 to over $900, with expectations to exceed $1,000 in Q2 [16] Energy Storage Innovations - A new compressed air energy storage compressor, developed by the Chinese Academy of Sciences, has achieved international leading levels, with over 100% increase in single-machine power [17] - This technology is expected to play a crucial role in supporting new energy systems and achieving carbon neutrality goals [17] Rare Earth Market - Prices of rare earth products have accelerated, with praseodymium-neodymium oxide and metal prices rising by 7.59% and 6.27% respectively [19] - The cumulative increase in praseodymium-neodymium oxide this year has reached 34% [19] Company Announcements - Zhongke Shuguang plans to issue convertible bonds to raise up to 8 billion yuan for AI-related projects [20] - Yuanjie Technology intends to invest 1.251 billion yuan in a semiconductor chip and device production base [20] - Hainan Mining plans to acquire a 69.9% stake in Fengrui Fluorine Industry [20]

《科创板日报》2月10日讯 今日科创板早报主要内容有：高德打车被约谈；三星显示正考虑扩大OLED 面板产能；埃夫特：拟购买盛普股份100%股份。 交通运输新业态协同监管部际联席会议办公室约谈高德打车 交通运输新业态协同监管部际联席会议办公室组织对高德打车进行了约谈。约谈指出了高德打车对合作 网约车平台管理不到位、压低运价、应急处置不当等突出问题，并要求高德打车立即落实约谈要求，深 刻反思，采取针对性措施，确保全面整改到位，切实维护司机群体合法权益。 认购需求空前旺盛 Alphabet料通过发行美元债筹资200亿 《科创板日报》主播小K为您播报。 市场动态 习近平：建设社会主义现代化强国 关键在科技自立自强 9日上午，习近平总书记在位于北京亦庄的国家信创园考察科技创新工作，走进展厅察看人工智能、机 器人等科技创新成果展示，并同科研人员和科技企业负责人代表亲切交流。习近平说，建设社会主义现 代化强国，关键在科技自立自强。要充分发挥我们国家集中力量办大事的优势，把各种优质要素集合起 来攻关，加快解决突出短板问题，实现我们的战略目标。 七部门对头部平台企业和快递企业开展用工行政指导 人力资源社会保障部近日会同中央社会 ...